IP Library › Granted Patent US 11,365,414
Granted Patent B2
US 11,365,414 · App. 16/990,347 · Granted Jun 21, 2022

Methods of inducing insulin production

Inventor: Pål Sætrom (Trondheim, NO)
Assignee: MINA THERAPEUTICS LIMITED
C12N15/1136A61P5/50C12N15/11C12N15/113C12N15/1135C12N15/1138C12N2310/11C12N2310/113C12N2310/14C12N2310/3519
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,365,414
App. No.
16/990,347
Granted
Jun 21, 2022
Kind
B2
Abstract

The present invention provides a method of inducing insulin production in a cell by up-regulating a target gene involved in insulin production in said cell using an saRNA (short activating ribonucleic acid) which specifically targets a target antisense RNA transcript present in said cell.

Claims (11)

1. An saRNA which upregulates a target gene involved in insulin production in a cell, wherein the target gene is Neurogenin 3 (Ngn3), and wherein said saRNA comprises a strand of up to 30 nucleotides in length comprising a sequence selected from SEQ ID No. 11-14.

2. The saRNA of claim 1 , wherein said saRNA is a single-stranded RNA.

3. The saRNA of claim 1 , wherein said saRNA is a double-stranded RNA.

4. The saRNA of claim 3 , wherein each strand of the double-stranded RNA has 19 to 25 base pairs in length with 1-5 unpaired bases on each 3′ end of the strand forming a 3′ overhang.

5. The saRNA of claim 4 , wherein said 3′ overhand is formed of 2 uracils.

6. The saRNA of claim 1 , comprising at least one modification.

7. The saRNA of claim 1 , wherein the cell is induced to produce insulin in a glucose-responsive manner.

8. The saRNA of claim 1 , wherein the cell is induced to secrete insulin.

9. The saRNA of claim 1 , wherein the cell is an adult or embryonic stem cell, a pluripotent cell, a multipotent cell, or a somatic cell.

10. The saRNA of claim 1 , wherein the cell is a liver cell or a pancreatic cell.

11. A pharmaceutical composition comprising one or more saRNAs according to claim 1 .

Assignments (2)
SECURITY INTEREST Recorded Jan 30, 2023
From: MINA (HOLDINGS) LIMITED; MINA THERAPEUTICS LIMITED; MINA ALPHA LIMITED; MINA BETA LIMITED
To: BOOTSTRAP EUROPE 3.0 S.À R.L.
Reel/Frame 062547/0070 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 22, 2020
From: SÆTROM, PÅL
To: MINA THERAPEUTICS LIMITED
Reel/Frame 054134/0080 →
Priority Claims (2)
GB 1016989 · Oct 8, 2010 · national
GB 1103745 · Mar 7, 2011 · national
Continuity (4)
Division 15837377 · Dec 11, 2017
Division 14547317 · Nov 19, 2014
Continuation 13877968
Related Publication 20200362352A1 · Nov 19, 2020